Immune responses detected in urothelial carcinoma patients after vaccination with ny-eso-1 protein plus bcg and gm-csf

Journal of Immunotherapy

Volumn 31, Issue 9, 2008, Pages 849-857

  Sharma, Padmanee ^a   Bajorin, Dean F ^b   Jungbluth, Achim A ^c   Herr, Harry ^c   Old, Lloyd J ^d   Gnjatic, Sacha ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of Medicine   (United States)

^c Department of Urology ^*  (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clinical trial; NY ESO 1; T cells; Urothelial carcinoma patients; Vaccine

Indexed keywords

BCG VACCINE; CANCER VACCINE; CTAG1B PROTEIN, HUMAN; EPITOPE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR ANTIGEN;

ANTIBODY PRODUCTION; ARTICLE; BLADDER TUMOR; CARCINOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EPITOPE MAPPING; ERYTHEMA; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; MALE; METABOLISM; PATHOLOGY; SECRETION; UROTHELIUM;

ADJUVANTS, IMMUNOLOGIC; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; BCG VACCINE; CANCER VACCINES; CARCINOMA; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPE MAPPING; EPITOPES; ERYTHEMA; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRADERMAL; INTERFERON-GAMMA; MALE; MEMBRANE PROTEINS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 63549129407     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181891574     Document Type: Article

References (31)

1. Parekh DP, Bochner BH, Dalgagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol. 2006;24:5519-5527.
2. Sharma P, Donat MS, Herr H, et al. Treatment of locally advanced bladder cancer. Princ Pract Oncol Updates. 2001;6:1.
3. Herr HW, Wartinger DD, Fair WR, et al. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol. 1992;147:1020-1023.
4. Amling CL, Thrasher JB, Frazier HA, et al. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol. 1994;151:31-36.
5. Soloway MS. Overview of treatment of superficial bladder cancer. Urology. 1985;26:18-26.
6. Cheng L, Weaver AL, Leibovich BC, et al. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer. 2000;88:2326-2332.
7. Pagliaro L, Sharma P. Review of metastatic bladder cancer. Minerva Urol Nefrol. 2006;58:53-71.
8. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 2007;104:3967-3972.
9. Sharma P, Gnjatic S, Jungbluth A, et al. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun. 2003;3:19.
10. Gnjatic S, Nishikawa H, Jungbluth A, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1-30.
11. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1.
12. Jungbluth AA, Chen YT, Stocker E. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer. 2001;92:856-860.
13. Sharma P, Shen Y, Wen S, et al. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res. 2006;12:5442-5447.
14. Gnjatic S, Nagata Y, Jager E, et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci USA. 2000;97:10917-10922.
15. Stockert E, Kager E, Chen YI, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998;187:1349-1354.
16. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA. 2003;100:8862-8867.
17. Atanackovic D, Matsuo M, Ritter E, et al. Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. J Immunol Methods. 2003;278:57-66.
18. + T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA. 2000;97:12198-12203.
19. + T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci USA. 2002;99:11813-11818.
20. Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA. 2005;102:9734.
21. Valmori D, Souleimanian NE, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8T cells through cross-priming. Proc Natl Acad Sci USA. 2007;104:8947-8952.
22. Atanackovic D, Altorki NK, Cao Y, et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA. 2008;105:1650-1655.
23. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8:247-258.
24. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211:214-224.
25. Stockinger B, Bourgeois C, Kassiotis G. CD4+ memory T cells: functional differentiation and homeostasis. Immunol Rev. 2006;211:39-48.
26. Adams S, O'Neill DW, Nonaka D, et al. Immunotherapy for malignant melanoma using recombinant NY-ESO-1 protein and Toll-like receptor 7 agonist imiquimod as vaccine adjuvant. J Immunol. 2008;181:776-784.
27. Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother. 2004;27:184-190.
28. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8T cells in patients with melanoma. J Immunol. 2005;175:6169-6176.
29. Diefenbach CSM, Gnjatic S, Sabbatini P, et al. Safety and immunogenicity study of NY-ESO1b peptide and Montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res. 2008;14:2740-2748.
30. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297-339.
31. Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high-risk bladder cancer. Semin Oncol. 2007;34:165-172.